XOMA to Present at the Cantor Fitzgerald Healthcare Conference
BERKELEY, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the Company’s Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12, 2016, at 9:30 a.m. ET.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 60 days following the presentation.
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism and in patients who experience hypoglycemia following gastric bypass surgery. For more information, visit www.xoma.com.
Company and Investor Contact: Ashleigh Barreto 510-204-7482 firstname.lastname@example.org Juliane Snowden The Oratorium Group, LLC email@example.com Media Contact: Taryn Ibach W2O Group 415-658-9748 firstname.lastname@example.org
Released July 5, 2016